Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival

Detalles Bibliográficos
Autores principales: Weber, Jeffrey S., Poretta, Tayla, Stwalley, Brian D., Sakkal, Leon A., Du, Ella X., Wang, Travis, Chen, Yan, Wang, Yan, Betts, Keith A., Shoushtari, Alexander N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025208/
https://www.ncbi.nlm.nih.gov/pubmed/36538061
http://dx.doi.org/10.1007/s00262-022-03351-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025208/
https://www.ncbi.nlm.nih.gov/pubmed/36538061
http://dx.doi.org/10.1007/s00262-022-03351-w

Ejemplares similares